Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Curaleaf's Boris Jordan Says Rescheduling Cannabis Will Save His Company $200M In Revenue, Bring Illicit Market In From The Cold (CORRECTED)

Published 17/05/2024, 21:03
© Reuters.  Curaleaf's Boris Jordan Says Rescheduling Cannabis Will Save His Company $200M In Revenue, Bring Illicit Market In From The Cold (CORRECTED)
CURA
-
CURLF
-

Benzinga - by Maureen Meehan, Benzinga Editor.

Editor’s note: The amount projected by Mr. Jordan refers to Curaleaf’s annual revenue, not that of the entire industry as previously stated.

Boris Jordan, founder and executive chairman of the board of Curaleaf Holdings, Inc. (CSE:CURA) (OTCQX:CURLF) spoke with CNBC's Squawk on the Street Friday about President Joe Biden's plan to reclassify cannabis to a Schedule III substance.

Jordan opened the conversation by saying this time it seems the government is taking a much more serious approach, "one based on science."

"This decision is important for two reasons. The first is, is that it will allow for research, very much needed medical research on this plant and the various cannabinoids in this plant," said Jordan, adding that government-funded research can presumably be undertaken once cannabis is moved to a Schedule III substance.

And Then There's The IRS

In addition to helping the industry in terms of safety and research there is the black market and the IRS. Jordan explains how they're connected.

"Consumers today are buying black market products because it is cheap because of this capricious tax that we have to pay," Jordan said. "We will be able to bring down prices forcing consumers to go to the regulated market where products are safe and tested. And also, social equity licenses, small entrepreneurs, they can't operate in this industry due to this tax, they will also be able to prosper and that's really important for the industry."

Jordan talked about how rescheduling relieves the cannabis industry of the ‘capricious and unconstitutional 280e tax which has been burdening the industry over the last 10 years."

Which Means?

Jordan broke it down with some shockingly large dollar amounts being unfairly paid by the industry and what it will mean when the pain stops.

"The industry pays approximately a 70 to 75% tax," Jordan said, whereas "other companies in the United States pay a 20 to 22% tax. So, it has a very profound effect on the industry.” To put it in perspective, relieving, or rescinding this tax, he said, will contribute to $150 to $200 million to Curaleaf’s bottom line of this year's projected revenue.

Illicit Market Vs. Legal Market: Will The Twain Ever Meet?

Jordan indicated that the twain will indeed meet or at least it should. In terms of the booming illicit cannabis market, he told CBNC that the change in marijuana's schedule is going to help the industry strike a balance.

$70 Billion Vs. $30 Billion

The U.S. industry is estimated to be worth approximately $100 billion or more. That said, Jordan pointed out that the illicit cannabis market pulls in $70 billion a year whereas the regulated earns around $30 billion. "That illicit market today will most likely start moving into the legal regulated market therefore giving regulated players much more strength to operate, much better financial help which I think will lead to consolidation in the industry and a lot more entrepreneurship." That in turn will enable "new businesses, craft growers craft companies to develop because they'll be able to write off their expenses and not pay exorbitant high taxes," he concluded.

Sounds like a win-win.

Boris Jordan has been a keynote speaker at numerous Benzinga Cannabis Conferences so you will likely run into him at the upcoming the Benzinga Cannabis Capital Conference in Chicago this October 8-9. Meet other top executives like Jordan as well as with investors, policymakers and advocates to explore the industry's seemingly bright future. Get your tickets now before prices increase by following this link.

Now Read: EXCLUSIVE – System Of A Down’s Shavo On Cannabis Rescheduling: ‘Still A Long Way To Go But It’s A Huge Milestone’

Photo: Benzinga

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.